****

**Veronica Anania, PhD**

**Senior Principal Scientist, Director of Mass Spectrometry and Clinical Proteomics**

**Genentech, Inc.**

**Dept. of Translational Medicine**

Veronica Anania, PhD is an experienced scientist specializing in biomarker mass spectrometry and clinical proteomics. As Director and Senior Principal Scientist at Genentech, she leads teams in developing biomarker strategies for multiple therapeutic areas including rheumatology and autoimmunity. Veronica's expertise in quantitative mass spectrometry, biomarker discovery, and assay development has driven innovative research in the field of clinical proteomics. Notable recent achievements from her team include deeply profiling disease proximal samples in large clinical cohorts from patients with IBD, AD, and Multiple Sclerosis to identify non-invasive biomarkers that positively impact drug development and patient care.

Veronica received her Bachelors in Science in Molecular Biology from the University of California Santa Cruz, and her Ph.D. in Molecular and Cellular Biology from the

University of California Berkeley where she studied immunological responses to viral pathogens. She then did a postdoctoral fellowship at Genentech with Dr. Jennie Lill where she learned to apply mass spectrometry and proteomics techniques to better understand cancer and human immunology. In 2014, she began her lab in the department of Translational Medicine at Genentech and now leads a team of ~10 researchers who utilize mass spectrometry to probe biomarker hypothesis to support clinical programs that span the entire drug development pipeline.